share_log

藥明康德：翌日披露報表

WUXI APPTEC: Next Day Disclosure Return

香港交易所 ·  Apr 1 18:27
Summary by Futu AI
無錫藥明康德新藥開發股份有限公司於2024年3月8日至4月1日期間，通過上海證券交易所回購共計859,260股A股股份，涉及總金額約為人民幣4009萬元。該公司在此期間內的股份回購價格介於人民幣45.89元至47.81元之間。此外，公司亦於2024年3月29日及4月1日根據2019年A股激勵計劃行使股票期權，發行了新的A股普通股股票。藥明康德的此次股份回購行動是根據相關規則進行，並已於翌日披露報表中公告。
無錫藥明康德新藥開發股份有限公司於2024年3月8日至4月1日期間，通過上海證券交易所回購共計859,260股A股股份，涉及總金額約為人民幣4009萬元。該公司在此期間內的股份回購價格介於人民幣45.89元至47.81元之間。此外，公司亦於2024年3月29日及4月1日根據2019年A股激勵計劃行使股票期權，發行了新的A股普通股股票。藥明康德的此次股份回購行動是根據相關規則進行，並已於翌日披露報表中公告。
Between March 8 and April 1, 2024, Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. repurchased a total of 859,260 shares of A-shares through the Shanghai Stock Exchange, involving a total amount of approximately RMB 400,000. The share repurchase price of the company during this period ranged from RMB45.89 to $47.81. In addition, the Company issued new shares of A common stock on 29 March 2024 and 1 April 2024 under the 2019 A Share Incentive Scheme. This share repurchase of Pharma Kund was conducted in accordance with the relevant rules and was announced in the following day's disclosure report.
Between March 8 and April 1, 2024, Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. repurchased a total of 859,260 shares of A-shares through the Shanghai Stock Exchange, involving a total amount of approximately RMB 400,000. The share repurchase price of the company during this period ranged from RMB45.89 to $47.81. In addition, the Company issued new shares of A common stock on 29 March 2024 and 1 April 2024 under the 2019 A Share Incentive Scheme. This share repurchase of Pharma Kund was conducted in accordance with the relevant rules and was announced in the following day's disclosure report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.